Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Spruce Biosciences Inc (NQ: SPRB )

0.5097 -0.0003 (-0.06%)
Streaming Delayed Price Updated: 12:36 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 181,300
Open 0.5011
Bid (Size) 0.5017 (20)
Ask (Size) 0.5097 (5)
Prev. Close 0.5100
Today's Range 0.4880 - 0.5099
52wk Range 0.4112 - 5.950
Shares Outstanding 40,710,692
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Spruce Biosciences, Inc.
Via Business Wire
SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q2 2024
SPRB stock results show that Spruce Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-82.78%
-82.78%
1 Month
+12.89%
+12.89%
3 Month
-6.65%
-6.65%
6 Month
-27.29%
-27.29%
1 Year
-62.93%
-62.93%

More News

Read More
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
Via AB Newswire
Spruce Biosciences Recognized as a Bay Area Best Place to Work
From Spruce Biosciences, Inc.
Via Business Wire
Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder
Via Benzinga
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society
From Spruce Biosciences, Inc.
Via Business Wire
SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in May Investor Conferences
From Spruce Biosciences, Inc.
Via Business Wire
Pfizer Q1 Earnings and Revenues Beat Estimates
Via Talk Markets
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Spruce Biosciences' Hormone Treatment Stumbles In Trials, Prompts Stock Freefall
Via Benzinga
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Dow Dips Over 100 Points; Dick's Sporting Goods Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Crude Oil Moves Higher; Dollar General Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
US Stocks Higher; Producer Prices Rise 0.6% In February
Via Benzinga
Topics Stocks
Exposures US Equities
Is Altria Giving Up on Anheuser-Busch (BUD) Stock?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.